In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
about
Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.Inhibition of G-protein βγ signaling enhances T cell receptor-stimulated interleukin 2 transcription in CD4+ T helper cellsB-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cellsPentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy.Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cellsChallenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengueAscitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.Targeting CD8+ T-cell tolerance for cancer immunotherapy.Agents that increase AAM differentiation blunt RSV-mediated lung pathology.Lysis of primary hepatic tumours by lymphokine activated killer cellsAdministration in vivo of recombinant interleukin 2 protects mice against septic death.Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastasesInterleukin-2 is present in human blood vessels and released in biologically active form by heparanase.The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatmentSelective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.Transgenic mice in the study of cytokine functionAnticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.Systemic immunological effects of cytokine genes injected into skeletal muscle.Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemiaPassive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2.Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model.Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphomaModulation of cellular immune responses in mice with disseminated histoplasmosis by recombinant interleukin-2Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells.Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.Safety and immunologic effects of IL-15 administration in nonhuman primates.Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperatureThe clinical potential of interleukin-2.Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.
P2860
Q24548127-6A912CC0-24F0-4A5C-9595-CBC6609ABCE2Q28543127-80BD0E4E-67BB-4347-8370-9976C90195FEQ29620717-CEDCFB6C-0835-459D-AFCB-4F36A8632DEDQ33370145-E2F7F32E-14AB-4CAB-80E0-06F9A660CEC8Q33705698-5460213E-D512-439D-AF0B-CFA38839B56DQ33811204-4040D8FB-1B0C-4165-ADC9-6897947EA730Q34077847-99E7C181-61D4-483D-886F-15BD4795CC16Q34207386-8C0414E6-8BA8-402A-BA7A-A47D75387D3AQ34260479-8F7C1853-4A98-420C-A20E-BA8386A89342Q34432692-30A5F4B4-E5E2-4836-A251-C797C849417BQ34484085-037EB455-463A-476C-B098-ACC7552F5078Q34527814-1D9E4611-8A15-48C1-A77D-C8A304EE406DQ34576288-488CB046-6ED6-487C-99B2-78FF887DFE48Q34577127-FB021930-4F9A-4F65-B6F0-694C541B74F6Q35181984-85A0D93D-93C0-4D93-B2CE-7A85CE7103DDQ35657649-6B2ABC51-CA53-48E3-961F-6CF9D765ED5FQ35823805-E4028FAB-0465-4685-9F16-7C4354841694Q35856332-35D5FA5F-AB80-41E7-B567-C3B253FF2C42Q35862775-F89A6713-C0A1-4AC8-8670-5D4B97DEC569Q35976681-7FDC0C29-E87B-4A51-8ABF-8EA4D827F0F6Q35993098-56BABC8F-1F94-4ED5-A035-069579615C31Q36029215-7456BE05-EC7B-4DEE-ACAB-F715732D55BEQ36293343-7858B515-02EA-4D08-98E9-4D6E413C916DQ36302958-21A8B4FB-FBD8-450C-9378-F79BC238CD17Q36355851-9CAA0633-367F-4E6F-B1E7-4CDF1B7B2DCBQ36356738-45414EC8-4A06-4EEB-A8C0-24B713B2FA17Q36421963-C913ABAA-7845-463A-AAB9-BD828F13FA82Q36586115-328828DD-359D-4BFA-B825-4387EAE47599Q36781968-42CA9756-63AE-4E5A-9B33-B8191A2CB3F5Q36940633-1ECC52DC-500D-4B5B-B2BF-4534B94C527AQ36956269-6F4441B1-D199-45A6-A069-2BB4175F7B40Q37010499-855D9550-D11D-47F8-99C7-89B456207733Q37129943-42F87026-2AFD-45B0-941D-C2F41C0155DEQ37251467-729F85BC-5C37-4331-A068-23DDE298B422Q37340647-F5BEE575-3A79-4774-9FAF-613CB15D1DD0Q37352474-D726A4CF-DC6F-4A29-A6DE-5B5BA5D6C5EBQ37395218-72B75BA1-7994-43EC-B6A7-3ECCA01EABBFQ39550760-D8BD01C5-614F-4390-913E-6F745BA9EE1CQ40790546-9BA2EE69-AA70-40E1-901E-AA925D81EDB2Q41706967-E80DEA2A-FB47-48F8-822A-1044DE745E59
P2860
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
In vivo administration of puri ...... in vivo with recombinant IL 2.
@en
type
label
In vivo administration of puri ...... in vivo with recombinant IL 2.
@en
prefLabel
In vivo administration of puri ...... in vivo with recombinant IL 2.
@en
P2093
P1476
In vivo administration of puri ...... in vivo with recombinant IL 2.
@en
P2093
Ettinghausen SE
Rosenberg SA
Sharrow SO
P304
P407
P577
1985-10-01T00:00:00Z